376 related articles for article (PubMed ID: 28059093)
1. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.
Enwere EK; Kornaga EN; Dean M; Koulis TA; Phan T; Kalantarian M; Köbel M; Ghatage P; Magliocco AM; Lees-Miller SP; Doll CM
Mod Pathol; 2017 Apr; 30(4):577-586. PubMed ID: 28059093
[TBL] [Abstract][Full Text] [Related]
2. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.
Heeren AM; Punt S; Bleeker MC; Gaarenstroom KN; van der Velden J; Kenter GG; de Gruijl TD; Jordanova ES
Mod Pathol; 2016 Jul; 29(7):753-63. PubMed ID: 27056074
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 Expression in Endocervical Adenocarcinoma: Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes.
Rivera-Colon G; Chen H; Molberg K; Niu S; Strickland AL; Castrillon DH; Carrick K; Gwin K; Lea J; Zheng W; Lucas E
Am J Surg Pathol; 2021 Jun; 45(6):742-752. PubMed ID: 33298732
[TBL] [Abstract][Full Text] [Related]
5. Uncovering PD-L1 and CD8
Chen J; Gu P; Wu H
Biomed Res Int; 2020; 2020():8164365. PubMed ID: 32884946
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.
Saglam O; Zhou J; Wang X; Conejo-Garcia JR
Int J Gynecol Pathol; 2020 Sep; 39(5):428-435. PubMed ID: 31274701
[TBL] [Abstract][Full Text] [Related]
7. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
[TBL] [Abstract][Full Text] [Related]
8. Programmed death-ligand 1 expression in human papillomavirus-independent cervical adenocarcinoma and its prognostic significance.
Chen L; Lucas E; Zhang X; Liu Q; Zhuang Y; Lin W; Chen H; Zhou F
Histopathology; 2022 Jan; 80(2):338-347. PubMed ID: 34455625
[TBL] [Abstract][Full Text] [Related]
9. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas.
Reddy OL; Shintaku PI; Moatamed NA
Diagn Pathol; 2017 Jun; 12(1):45. PubMed ID: 28623908
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8
Lim YJ; Koh J; Kim S; Jeon SR; Chie EK; Kim K; Kang GH; Han SW; Kim TY; Jeong SY; Park KJ; Wu HG
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1216-1224. PubMed ID: 29165286
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
[TBL] [Abstract][Full Text] [Related]
12. PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.
Varki V; Ioffe OB; Bentzen SM; Heath J; Cellini A; Feliciano J; Zandberg DP
Cancer Immunol Immunother; 2018 May; 67(5):805-814. PubMed ID: 29484464
[TBL] [Abstract][Full Text] [Related]
13. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
14. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F
Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183
[TBL] [Abstract][Full Text] [Related]
15. Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix.
Zong L; Zhang Q; Zhou Y; Kong Y; Yu S; Chen J; Zhang Y; Xiang Y
J Immunol Res; 2020; 2020():1283632. PubMed ID: 32322590
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
Song F; Jia M; Yu S; Cao L; Sun PL; Gao H
Histopathology; 2021 Nov; 79(5):861-871. PubMed ID: 34156708
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
19. Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy.
Tsuchiya T; Someya M; Takada Y; Hasegawa T; Kitagawa M; Fukushima Y; Gocho T; Hori M; Nakata K; Hirohashi Y; Torigoe T; Saito T; Sakata KI
Strahlenther Onkol; 2020 Aug; 196(8):725-735. PubMed ID: 31953603
[TBL] [Abstract][Full Text] [Related]
20. The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression.
Chen MF; Chen PT; Chen WC; Lu MS; Lin PY; Lee KD
Oncotarget; 2016 Feb; 7(7):7913-24. PubMed ID: 26761210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]